MAZE•benzinga•
JP Morgan Initiates Coverage On Maze Therapeutics with Overweight Rating, Announces Price Target of $30
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 25, 2025 by benzinga